Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial

Basit Öğe Kaydı
dc.contributor.authorYılmaz, İlkay
dc.contributor.authorDolar, M. Enver
dc.contributor.authorÖzpınar, Haydar
dc.date.accessioned2024-06-13T20:18:40Z
dc.date.available2024-06-13T20:18:40Z
dc.date.issued2019
dc.departmentEnstitüler, Lisansüstü Eğitim Enstitüsü, Beslenme ve Diyetetik Ana Bilim Dalı
dc.description.abstractBackground/Aims: Kefir is a kind of fermented probiotic dairy product. The objective of the present study was to investigate the effects of kefir consumption on the fecal microflora and symptoms of patients with inflammatory bowel disease (IBD). Materials and Methods: Kefir was serially diluted and inoculated into de Man, Rogosa, and Sharpe agar and incubated at 37 degrees C for 48 to 72 h under anaerobic conditions. This was a single-center, prospective, open-label randomized controlled trial. Forty-five patients with IBD were classified into two groups: 25 for treatment and 20 for control. A 400 mL/day kefir was administered to the patients for 4 weeks day and night. Their stool Lactobacillus, Lactobacillus kefiri, content was quantitated by real-time quantitative polymerase chain reaction before and after consumption. Abdominal pain, bloating, stool frequency, stool consistency, and feeling good scores were recorded in diaries daily by the patients. Results: A 5x10(7) CFU/mL count of lactic acid bacteria colony forming units was found in a kefir sample as the total average count. Lactobacillus bacterial load of feces of all subjects in the treatment group was between 10(4) and 10(9) CFU/g, and the first and last measurements were statistically significant (p=0.001 in ulcerative colitis and p=0.005 in Crohn's disease (CD)). The L. kefiri bacterial load in the stool of 17 subjects was measured as between 10(4) and 10(6) CFU/g. For patients with CD, there was a significant decrease in erythrocyte sedimentation rate and C-reactive protein, whereas hemoglobin increased, and for the last 2 weeks, bloating scores were significantly reduced (p=0.012), and feeling good scores increased (p=0.032). Conclusion: According to our data, kefir consumption may modulate gut microbiota, and regular consumption of kefir may improve the patient's quality of life in the short term.
dc.identifier.doi10.5152/tjg.2018.18227
dc.identifier.endpage253
dc.identifier.issn2148-5607
dc.identifier.issue3
dc.identifier.pmid30662004
dc.identifier.scopus2-s2.0-85064106890
dc.identifier.scopusqualityQ3
dc.identifier.startpage242
dc.identifier.trdizinid298131
dc.identifier.urihttps://doi.org/10.5152/tjg.2018.18227
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/298131
dc.identifier.urihttps://hdl.handle.net/11501/1462
dc.identifier.volume30
dc.identifier.wosWOS:000462167400005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorÖzpınar, Haydar
dc.institutionauthorid0000-0002-2523-7149
dc.language.isoen
dc.publisherAVES
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInflammatory Bowel Disease
dc.subjectKefir
dc.subjectLactobacillus
dc.subjectLactobacillus Kefiri
dc.subjectProbiotics
dc.titleEffect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
222.33 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Lisansüstü Eğitim Enstitüsü Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu